Navigation Links
Cephalon to Webcast Investor Day
Date:11/12/2010

FRAZER, Pa., Nov. 12, 2010 /PRNewswire-FirstCall/ --Cephalon, Inc. (Nasdaq: CEPH) today announced that its Investor Day in New York City, to be held on November 18, 2010, will be webcast live on the investor relations section of its website at www.cephalon.com.

Cephalon's senior management will review the company's business strategy, marketing plan and research and development initiatives.  The presentation will be delivered on Thursday, November 18, 2010, beginning at 12:00 noon and ending at approximately 3:00 p.m. EST.  To access the webcast, log on to the company's website at www.cephalon.com and click on "Investors," then "Webcast."  Click on the link and follow the prompts for registration and access. The webcast replay will be available for one week following the broadcast.  

About Cephalon, Inc.Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world.  Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.  Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide.  The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.
More information on Cephalon and its products is available at http://www.cephalon.com

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion. Investor contacts:Robert (Chip) Merritt610-738-6376cmerritt@cephalon.comJoseph Marczely610-883-5894jmarczely@cephalon.com
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
2. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
3. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
4. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
5. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
6. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
7. Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position
8. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
9. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
10. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
11. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
(Date:3/29/2017)... AMSTERDAM , March 29, 2017   ... global leader in health technology, and PathAI, a ... are collaborating with the aim to develop solutions ... diagnosis of cancer and other diseases. The partnership ... pathology, enabling this form of artificial intelligence to ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... ... ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is now ... without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. Horeb, ... receive early treatment, they may achieve straight teeth with less treatment in their teenage ...
(Date:3/29/2017)... Md., and MINNETONKA, Minn. (PRWEB) , ... March ... ... the development of medical office buildings (MOBs) and other outpatient facilities, and who ... project to look exclusively at those questions, Revista and Healthcare Real Estate Insights ...
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
(Date:3/29/2017)... ... , ... HealthCareMandA.com will host an important webinar — Home Health & Hospice: ... recording of the webinar will also be made available following its live presentation. The ... are still popular targets for healthcare investors. This highly fragmented sector bounced back in ...
Breaking Medicine News(10 mins):